Fig. 2

IL20RB promotes stemness and chemoresistance in pancreatic cancer in vitro. A Real-time quantitative PCR analysis of IL20RB mRNA expression in pancreatic cancer cell lines PANC-1 and MIA PaCa-2 (n = 3 in each group). B Western blot analysis of IL20RB protein expression in PANC-1 and MIA PaCa-2 (n = 3 in each group). C–D Sphere-forming assay and statistical analysis of PANC-1 and MIA PaCa-2 (n = 3 per group). E–F Flow cytometry and statistical analyses of side population cells in PANC-1 and MIA PaCa-2 (n = 3 in each group). G Real-time quantitative PCR analysis of IL20RB, NANOG, SOX2 and POU5F1 mRNA expression in PANC-1 and MIA PaCa-2 (n = 3 in each group). H Western blot analysis of IL20RB, NANOG and SOX2 protein expression in PANC-1 and MIA PaCa-2 (n = 3 in each group). I–J Results of colony formation assay and statistical analysis of pancreatic cancer cell lines treated with 10 nM gemcitabine for 24 h. K–L Representative immunofluorescence images and statistical analysis of IL20RB, NANOG and SOX2 in human pancreatic cancer tissue sections, scale bar = 40 µm